Denne side blev automatisk oversat, og nøjagtigheden af oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan

28. februar 2014 opdateret af: Boehringer Ingelheim

Additional Effect of a Life Style Program on Antihypertensive Treatment With Telmisartan

This post-marketing surveillance study is designed to supplement the data on efficacy and tolerability of Micardis® and MicardisPlus® in patients at cardiovascular risk under general practice conditions.

The aim of the study is to investigate the effect of a six-month treatment with Micardis® / MicardisPlus® on blood pressure and the effect of the Lifestyle education tool for weight reduction on blood pressure control.

In addition, the post-marketing surveillance study will provide information on the effects on target measurement of the Lifestyle education tool and various laboratory parameters produced by treatment with Micardis® and MicardisPlus® in an unselected patient population under general practice conditions.

Studieoversigt

Status

Afsluttet

Betingelser

Forhøjet blodtryk

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

1856

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Slovenien
- - ?adca, Slovenien
    - Boehringer Ingelheim Investigational Site 34
  - Banská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 2
  - Banská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 3
  - Banská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 4
  - Banská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 5
  - Banská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 6
  - Banská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 7
  - Banská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 8
  - Bardejov, Slovenien
    - Boehringer Ingelheim Investigational Site 10
  - Bardejov, Slovenien
    - Boehringer Ingelheim Investigational Site 11
  - Bardejov, Slovenien
    - Boehringer Ingelheim Investigational Site 12
  - Bardejov, Slovenien
    - Boehringer Ingelheim Investigational Site 9
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 13
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 14
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 15
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 16
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 17
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 18
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 19
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 20
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 21
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 22
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 23
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 24
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 25
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 26
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 27
  - Bratislava, Slovenien
    - Boehringer Ingelheim Investigational Site 28
  - Brezno, Slovenien
    - Boehringer Ingelheim Investigational Site 29
  - Brezno, Slovenien
    - Boehringer Ingelheim Investigational Site 30
  - Brezno, Slovenien
    - Boehringer Ingelheim Investigational Site 31
  - Brezno, Slovenien
    - Boehringer Ingelheim Investigational Site 32
  - Byt?a, Slovenien
    - Boehringer Ingelheim Investigational Site 33
  - Bánovce nad Bebravou, Slovenien
    - Boehringer Ingelheim Investigational Site 1
  - Dolný Kubín, Slovenien
    - Boehringer Ingelheim Investigational Site 35
  - Dubnica nad Váhom, Slovenien
    - Boehringer Ingelheim Investigational Site 36
  - Dubnica nad Váhom, Slovenien
    - Boehringer Ingelheim Investigational Site 37
  - Dunajská Streda, Slovenien
    - Boehringer Ingelheim Investigational Site 38
  - Dunajská Streda, Slovenien
    - Boehringer Ingelheim Investigational Site 39
  - Dunajská Streda, Slovenien
    - Boehringer Ingelheim Investigational Site 40
  - Dunajská Streda, Slovenien
    - Boehringer Ingelheim Investigational Site 41
  - Dunajská Streda, Slovenien
    - Boehringer Ingelheim Investigational Site 42
  - Dunajská Streda, Slovenien
    - Boehringer Ingelheim Investigational Site 43
  - Galanta, Slovenien
    - Boehringer Ingelheim Investigational Site 44
  - Galanta, Slovenien
    - Boehringer Ingelheim Investigational Site 45
  - Handlová, Slovenien
    - Boehringer Ingelheim Investigational Site 46
  - Hlohovec, Slovenien
    - Boehringer Ingelheim Investigational Site 47
  - Hlohovec, Slovenien
    - Boehringer Ingelheim Investigational Site 48
  - Hnús?a, Slovenien
    - Boehringer Ingelheim Investigational Site 49
  - Hurbanovo, Slovenien
    - Boehringer Ingelheim Investigational Site 50
  - Jesenské, Slovenien
    - Boehringer Ingelheim Investigational Site 51
  - Kezmarok, Slovenien
    - Boehringer Ingelheim Investigational Site 52
  - Kolárovo, Slovenien
    - Boehringer Ingelheim Investigational Site 53
  - Komárno, Slovenien
    - Boehringer Ingelheim Investigational Site 54
  - Komárno, Slovenien
    - Boehringer Ingelheim Investigational Site 55
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 56
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 57
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 58
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 59
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 60
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 61
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 62
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 63
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 64
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 65
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 66
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 67
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 68
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 69
  - Kosice, Slovenien
    - Boehringer Ingelheim Investigational Site 70
  - Krá?ovský Chlmec, Slovenien
    - Boehringer Ingelheim Investigational Site 71
  - Kysucké Nové Mesto, Slovenien
    - Boehringer Ingelheim Investigational Site 72
  - Kysucké Nové Mesto, Slovenien
    - Boehringer Ingelheim Investigational Site 73
  - Kysucké Nové Mesto, Slovenien
    - Boehringer Ingelheim Investigational Site 74
  - Levice, Slovenien
    - Boehringer Ingelheim Investigational Site 75
  - Levice, Slovenien
    - Boehringer Ingelheim Investigational Site 76
  - Levice, Slovenien
    - Boehringer Ingelheim Investigational Site 77
  - Lipany, Slovenien
    - Boehringer Ingelheim Investigational Site 78
  - Lu?enec, Slovenien
    - Boehringer Ingelheim Investigational Site 79
  - Lu?enec, Slovenien
    - Boehringer Ingelheim Investigational Site 80
  - Lu?enec, Slovenien
    - Boehringer Ingelheim Investigational Site 81
  - Lu?enec, Slovenien
    - Boehringer Ingelheim Investigational Site 82
  - Martin, Slovenien
    - Boehringer Ingelheim Investigational Site 83
  - Martin, Slovenien
    - Boehringer Ingelheim Investigational Site 84
  - Martin, Slovenien
    - Boehringer Ingelheim Investigational Site 85
  - Michalovce, Slovenien
    - Boehringer Ingelheim Investigational Site 86
  - Michalovce, Slovenien
    - Boehringer Ingelheim Investigational Site 87
  - Michalovce, Slovenien
    - Boehringer Ingelheim Investigational Site 88
  - Myjava, Slovenien
    - Boehringer Ingelheim Investigational Site 89
  - Nitra, Slovenien
    - Boehringer Ingelheim Investigational Site 91
  - Nitra, Slovenien
    - Boehringer Ingelheim Investigational Site 92
  - Nitra, Slovenien
    - Boehringer Ingelheim Investigational Site 93
  - Nitra, Slovenien
    - Boehringer Ingelheim Investigational Site 94
  - Nové Mesto nad Váhom, Slovenien
    - Boehringer Ingelheim Investigational Site 95
  - Nové Mesto nad Váhom, Slovenien
    - Boehringer Ingelheim Investigational Site 96
  - Nové Mesto nad Váhom, Slovenien
    - Boehringer Ingelheim Investigational Site 97
  - Nové Zámky, Slovenien
    - Boehringer Ingelheim Investigational Site 100
  - Nové Zámky, Slovenien
    - Boehringer Ingelheim Investigational Site 101
  - Nové Zámky, Slovenien
    - Boehringer Ingelheim Investigational Site 98
  - Nové Zámky, Slovenien
    - Boehringer Ingelheim Investigational Site 99
  - Námestovo, Slovenien
    - Boehringer Ingelheim Investigational Site 90
  - Partizánske, Slovenien
    - Boehringer Ingelheim Investigational Site 102
  - Partizánske, Slovenien
    - Boehringer Ingelheim Investigational Site 103
  - Pezinok, Slovenien
    - Boehringer Ingelheim Investigational Site 104
  - Pies?any, Slovenien
    - Boehringer Ingelheim Investigational Site 105
  - Poprad, Slovenien
    - Boehringer Ingelheim Investigational Site 106
  - Poprad, Slovenien
    - Boehringer Ingelheim Investigational Site 107
  - Poprad, Slovenien
    - Boehringer Ingelheim Investigational Site 108
  - Povazská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 109
  - Povazská Bystrica, Slovenien
    - Boehringer Ingelheim Investigational Site 110
  - Presov, Slovenien
    - Boehringer Ingelheim Investigational Site 111
  - Presov, Slovenien
    - Boehringer Ingelheim Investigational Site 112
  - Presov, Slovenien
    - Boehringer Ingelheim Investigational Site 113
  - Presov, Slovenien
    - Boehringer Ingelheim Investigational Site 114
  - Prievidza, Slovenien
    - Boehringer Ingelheim Investigational Site 115
  - Prievidza, Slovenien
    - Boehringer Ingelheim Investigational Site 116
  - Prievidza, Slovenien
    - Boehringer Ingelheim Investigational Site 117
  - Rajec, Slovenien
    - Boehringer Ingelheim Investigational Site 118
  - Revúca, Slovenien
    - Boehringer Ingelheim Investigational Site 119
  - Revúca, Slovenien
    - Boehringer Ingelheim Investigational Site 120
  - Rimavská Sobota, Slovenien
    - Boehringer Ingelheim Investigational Site 121
  - Rimavská Sobota, Slovenien
    - Boehringer Ingelheim Investigational Site 122
  - Rimavská Sobota, Slovenien
    - Boehringer Ingelheim Investigational Site 123
  - Roz?ava, Slovenien
    - Boehringer Ingelheim Investigational Site 124
  - Roz?ava, Slovenien
    - Boehringer Ingelheim Investigational Site 125
  - Ruzomberok, Slovenien
    - Boehringer Ingelheim Investigational Site 126
  - Ruzomberok, Slovenien
    - Boehringer Ingelheim Investigational Site 127
  - Sa?a, Slovenien
    - Boehringer Ingelheim Investigational Site 128
  - Sa?a, Slovenien
    - Boehringer Ingelheim Investigational Site 129
  - Sa?a, Slovenien
    - Boehringer Ingelheim Investigational Site 130
  - Se?ovce, Slovenien
    - Boehringer Ingelheim Investigational Site 131
  - Se?ovce, Slovenien
    - Boehringer Ingelheim Investigational Site 132
  - Skalica, Slovenien
    - Boehringer Ingelheim Investigational Site 133
  - Snina, Slovenien
    - Boehringer Ingelheim Investigational Site 134
  - Snina, Slovenien
    - Boehringer Ingelheim Investigational Site 135
  - Spisská Nová Ves, Slovenien
    - Boehringer Ingelheim Investigational Site 136
  - Spisská Nová Ves, Slovenien
    - Boehringer Ingelheim Investigational Site 137
  - Stará ?ubov?a, Slovenien
    - Boehringer Ingelheim Investigational Site 138
  - Stará ?ubov?a, Slovenien
    - Boehringer Ingelheim Investigational Site 139
  - Stará ?ubov?a, Slovenien
    - Boehringer Ingelheim Investigational Site 140
  - Stropkov, Slovenien
    - Boehringer Ingelheim Investigational Site 141
  - Stúrovo, Slovenien
    - Boehringer Ingelheim Investigational Site 142
  - Surany, Slovenien
    - Boehringer Ingelheim Investigational Site 143
  - Surany, Slovenien
    - Boehringer Ingelheim Investigational Site 144
  - Svit, Slovenien
    - Boehringer Ingelheim Investigational Site 145
  - Topo??any, Slovenien
    - Boehringer Ingelheim Investigational Site 146
  - Torna?a, Slovenien
    - Boehringer Ingelheim Investigational Site 147
  - Trebisov, Slovenien
    - Boehringer Ingelheim Investigational Site 148
  - Trebisov, Slovenien
    - Boehringer Ingelheim Investigational Site 149
  - Trebisov, Slovenien
    - Boehringer Ingelheim Investigational Site 150
  - Tren?ín, Slovenien
    - Boehringer Ingelheim Investigational Site 151
  - Tren?ín, Slovenien
    - Boehringer Ingelheim Investigational Site 152
  - Tren?ín, Slovenien
    - Boehringer Ingelheim Investigational Site 153
  - Tren?ín, Slovenien
    - Boehringer Ingelheim Investigational Site 154
  - Trnava, Slovenien
    - Boehringer Ingelheim Investigational Site 155
  - Trnava, Slovenien
    - Boehringer Ingelheim Investigational Site 156
  - Trnava, Slovenien
    - Boehringer Ingelheim Investigational Site 157
  - Trnava, Slovenien
    - Boehringer Ingelheim Investigational Site 158
  - Trstená, Slovenien
    - Boehringer Ingelheim Investigational Site 159
  - Tur?ianske Teplice, Slovenien
    - Boehringer Ingelheim Investigational Site 160
  - Turzovka, Slovenien
    - Boehringer Ingelheim Investigational Site 161
  - Ve?ké Kapusany, Slovenien
    - Boehringer Ingelheim Investigational Site 162
  - Ve?ké Kapusany, Slovenien
    - Boehringer Ingelheim Investigational Site 163
  - Ve?ký Krtís, Slovenien
    - Boehringer Ingelheim Investigational Site 164
  - Ve?ký Krtís, Slovenien
    - Boehringer Ingelheim Investigational Site 165
  - Vranov nad Top?ou, Slovenien
    - Boehringer Ingelheim Investigational Site 167
  - Vráble, Slovenien
    - Boehringer Ingelheim Investigational Site 166
  - Zarnovica, Slovenien
    - Boehringer Ingelheim Investigational Site 168
  - Zeliezovce, Slovenien
    - Boehringer Ingelheim Investigational Site 169
  - Zilina, Slovenien
    - Boehringer Ingelheim Investigational Site 170
  - Zilina, Slovenien
    - Boehringer Ingelheim Investigational Site 171
  - Zilina, Slovenien
    - Boehringer Ingelheim Investigational Site 172
  - Zilina, Slovenien
    - Boehringer Ingelheim Investigational Site 173
  - Zilina, Slovenien
    - Boehringer Ingelheim Investigational Site 174
  - Zilina, Slovenien
    - Boehringer Ingelheim Investigational Site 175
  - Zlaté Moravce, Slovenien
    - Boehringer Ingelheim Investigational Site 176
  - Zlaté Moravce, Slovenien
    - Boehringer Ingelheim Investigational Site 177
  - Zlaté Moravce, Slovenien
    - Boehringer Ingelheim Investigational Site 178
  - Zvolen, Slovenien
    - Boehringer Ingelheim Investigational Site 179
  - Zvolen, Slovenien
    - Boehringer Ingelheim Investigational Site 180
  - Zvolen, Slovenien
    - Boehringer Ingelheim Investigational Site 181
  - Zvolen, Slovenien
    - Boehringer Ingelheim Investigational Site 182

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Patients with hypertension

Beskrivelse

Inclusion criteria:

Patients with essential hypertension (blood pressure (BP) higher or equal to 140/90 mmHg or higher or equal to 130/80 mmHg in case of diabetic patients)
Patients with hypertension under treatment with one or more antihypertensive drug

Exclusion criteria:

Patients are excluded according to the summary of product characteristics (SmPC).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Antal grupper/kohorter

Kohorter og interventioner

Gruppe / kohorte
Patients at cardiovascular risk

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål	Foranstaltningsbeskrivelse	Tidsramme
Changes in Mean Blood Pressure (Systolic) After Treatment, Compared to Baseline Tidsramme: 24 weeks (Visit 1 to Visit 3)	Changes in blood pressure in patients with systolic values, measured at baseline and final visit, by treatment and by Tool/No Tool	24 weeks (Visit 1 to Visit 3)
Changes in Mean Blood Pressure (Diastolic) After Treatment, Compared to Baseline Tidsramme: 24 weeks (Visit 1 to Visit 3)	Changes in blood pressure in patients with diastolic values, measured at baseline and final visit, by treatment and by Tool/No Tool	24 weeks (Visit 1 to Visit 3)

Sekundære resultatmål

Resultatmål	Foranstaltningsbeskrivelse	Tidsramme
Changes in Laboratory Parameters:Low Density Lipoprotein (LDL) Tidsramme: 24 weeks (Visit 1 to Visit 3)	Changes in LDL cholesterol levels from baseline to final visit in patients with both laboratory values valid, by treatment and by Tool/No Tool	24 weeks (Visit 1 to Visit 3)
Changes in Laboratory Parameters:High Density Lipoprotein (HDL) Tidsramme: 24 weeks (Visit 1 to Visit 3)	Changes in LDL cholesterol levels from baseline to final visit in patients with both laboratory values valid, by treatment and by Tool/No Tool	24 weeks (Visit 1 to Visit 3)
Changes in Laboratory Parameters: Triglycerides Tidsramme: 24 weeks (Visit 1 to Visit 3)	Changes in the triglyceride levels from baseline to final visit in patients with both laboratory values valid, by treatment and by Tool/No Tool	24 weeks (Visit 1 to Visit 3)
Changes in Laboratory Parameters: Blood Glucose Tidsramme: 24 weeks (Visit 1 to Visit 3)	Changes in the fasting blood glucose levels from baseline to final visit in patients with both laboratory values valid, by treatment and by Tool/No Tool	24 weeks (Visit 1 to Visit 3)
Assessment of Metabolic Effect Tidsramme: 24 weeks (Visit 1 to Visit 3)	Metabolic effect was rated by the investigators as 'positive', 'neutral' and 'negative'	24 weeks (Visit 1 to Visit 3)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Boehringer Ingelheim

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Related Info

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2008

Primær færdiggørelse (Faktiske)

1. september 2009

Studieafslutning (Faktiske)

1. september 2009

Datoer for studieregistrering

Først indsendt

11. marts 2010

Først indsendt, der opfyldte QC-kriterier

21. april 2010

Først opslået (Skøn)

22. april 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

10. april 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. februar 2014

Sidst verificeret

1. februar 2014

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

502.579

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Forhøjet blodtryk

Bayer

Afsluttet

Post-marketing overvågning af Ventavis® hos kinesiske patienter med primær pulmonal hypertension (PPH)

Primær hypertension

Kina
National Taiwan University Hospital Hsin-Chu Branch

Rekruttering

Bærbare blodtryksenheder til at identificere maskeret ukontrolleret hypertension.

Hypertension, essentiel | Hypertension, maskeret

Taiwan
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Afsluttet

Kronisk trombo-embolisk pulmonal hypertension: Klassificering og langsigtet resultat

Idiopatisk pulmonal arteriel hypertension | Kronisk tromboembolisk pulmonal hypertension

Det Forenede Kongerige
University of Kansas Medical Center

Rekruttering

Pulmonal Hypertension Biorepository og Registry (PHBR)

Pulmonal arteriel hypertension | Pulmonal hypertension | Kronisk tromboembolisk pulmonal hypertension | Pulmonal hypertension på grund af venstre hjertesygdom | Pulmonal hypertension, primær, 4 | Pulmonal hypertension, primær, 2 | Pulmonal hypertension, primær, 3 | Pulmonal hypertension, primær | Pulmonal...

Forenede Stater
Papworth Hospital NHS Foundation Trust
Merck Sharp & Dohme LLC

Afsluttet

Serum biomarkører i pulmonal hypertension

Pulmonal hypertension, primær, 4

Det Forenede Kongerige
Centre Chirurgical Marie Lannelongue

Ukendt

Determinanter for ombygning af højre hjerte hos patienter med CTEPH eller PAH (PRINCEPT)

Kronisk trombo-embolisk pulmonal hypertension og pulmonal arteriel hypertension

Frankrig
University of South Florida

Trukket tilbage

Effektstudie af Cardizem ved pulmonal arteriel hypertension

Pulmonal arteriel hypertension | Familiær primær pulmonal hypertension | Idiopatisk pulmonal arteriel hypertension | Primær pulmonal hypertension

Forenede Stater
Heidelberg University
Merck Sharp & Dohme LLC

Rekruttering

Virkninger af Riociguat på højre ventrikulær størrelse og funktion i PAH og CTEPH (RIVERII)

Kronisk tromboembolisk pulmonal hypertension | Primær pulmonal arteriel hypertension

Tyskland
Columbia University
Agency for Healthcare Research and Quality (AHRQ)

Aktiv, ikke rekrutterende

Implementing Hypertension Screening Guidelines in Primary Care

White Coat Hypertension | Hypertension, essentiel

Forenede Stater
Amsterdam UMC, location VUmc
ZonMw: The Netherlands Organisation for Health Research and Development

Ukendt

Betablokkere i i-PAH

Idiopatisk pulmonal arteriel hypertension

Holland

Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan